Literature DB >> 12546440

Proton magnetic resonance spectroscopy in a case of subacute sclerosing panencephalitis.

Zenichiro Kato1, Kyoko Saito, Michiko Yamada, Takahiko Asano, Naomi Kondo.   

Abstract

Subacute sclerosing panencephalitis is an encephalopathy caused by a persistent measles virus infection. We examined a 13-year-old girl with subacute sclerosing panencephalitis and performed a magnetic resonance spectroscopic study to evaluate the in vivo pathophysiologic abnormality. The results suggested the occurrence of inflammatory processes and glial proliferation prior to neuronal loss even in magnetic resonance imaging (MRI)-negative regions as well as in MRI-positive regions. The additional resonance peaks were also detected, but further studies should be performed to determine the precise pathophysiologic mechanisms. Novel in vivo modalities such as spectroscopy would be useful as a tool to measure responses to therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12546440     DOI: 10.1177/08830738020170101809

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  4 in total

1.  Subacute sclerosing panencephalitis findings at MR imaging, diffusion MR imaging, and proton MR spectroscopy.

Authors:  R Nuri Sener
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

2.  18F-FDG PET and MRS of the early stages of subacute sclerosing panencephalitis in a child with a normal initial MRI.

Authors:  Yeong-Seon Seo; Ho-Sung Kim; Da-Eun Jung
Journal:  Pediatr Radiol       Date:  2010-03-17

3.  Proton magnetic resonance spectroscopy in three subacute sclerosing panencephalitis patients: correlation with clinical status.

Authors:  Handan Cakmakci; Semra Kurul; Akin Iscan; Eray Dirik
Journal:  Childs Nerv Syst       Date:  2004-02-04       Impact factor: 1.475

Review 4.  Chronic viral infections of the central nervous system: Aspects specific to multiple sclerosis.

Authors:  P Giraudon; A Bernard
Journal:  Rev Neurol (Paris)       Date:  2009-08-04       Impact factor: 2.607

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.